Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

to placebo or teriflunomide, 7mg or 14mg, once daily. The primary endpoint was annualized relapse rate defined as the number of confirmed relapses per patients-year. The key secondary endpoint was the time to disability progression measured by EDSS. Safety and tolerability evaluations were based on treatment emergent adverse events, physical examinations, vital signs and laboratory investigations.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, unpredictable and progressively disabling disease. Patients with MS typically are diagnosed at a young age and they face a lifetime of uncertainty with gradually declining health. Today, over two million people around the world suffer from MS. MS is the result of damage to myelin, a protective sheath surrounding nerve fibres of the central nervous system. When myelin is damaged, this interferes with messages between the brain and other parts of the body. Multiple sclerosis is a very variable condition and the symptoms depend on which areas of the central nervous system have been affected. There is no definite pattern to MS and everyone with MS has a different set of symptoms, which vary from time to time and can change in severity and duration, even in the same person. Management of MS is complex; early intervention in the pathological process is recommended in order to delay disease progression or at least, slow it down. A complex support system is required for the care of MS patients, including health and social services, as well as various healthcare professionals. Although there is no known cure for multiple sclerosis, several therapies are proven to be helpful but there remains an unmet need for new oral therapies with an acceptable benefit/risk profile.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CITY, Md. , July 29, 2014 /PRNewswire/ ... announced a new and updated program for the ... 10 – 12, 2014 in Amelia Island ... CROs, sites and investigators remains unchanged, however, the ... purposeful exchange and networking opportunity among all stakeholders ...
(Date:7/29/2014)... According to the new research ... (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & ... to 2018", published by MarketsandMarkets, analyzes and studies the ... North America , Europe ... Rest of the World (RoW). Browse 78 ...
(Date:7/29/2014)... PORTLAND, Oregon , July 29, 2014 ... titled, "Global surgical equipment market (types, applications and geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... expected to reach $12.1 billion by 2020 registering a ... Due to the breakthrough achieved by the electro surgical ...
(Date:7/29/2014)... July 29, 2014 TransVac Solutions, the ... collection and transport solutions for hospitals, will be exhibiting ... Engineering (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 ... its technology for making hospitals cleaner, reducing infection risk ... the hospital’s life cycle. Staff will be available ...
Breaking Biology Technology:TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... Nov. 17 Doctors Research Group, Inc. announced today ... Food and Drug Administration (FDA) to market KRYPTONITE(TM) Bone ... a major advancement in treating cranial defects due to ... exotherm cement and bone void filler approved for cranioplasty ...
... , SAN FRANCISCO, Nov. 17 Merriman Curhan Ford Group, ... in PolyMedix Inc.,s (OTC Bulletin Board: PYMX) $20.7 million registered ... priced at $1.00 per unit, consist of one share of ... 0.30 of a share of PolyMedix common stock at $1.25 ...
... TSX symbol: SBS , CALGARY, Nov. 17 /PRNewswire-FirstCall/ - ... Court of Queen,s Bench of Alberta has issued an ... of the securityholders of SemBioSys, at which securityholders will ... (the "Arrangement") involving the corporate reorganization with Cathedral Energy ...
Cached Biology Technology:Doctors Research Group Receives FDA Clearance for U.S. Distribution of KRYPTONITE(TM) Bone Cement 2Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing 2SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009 2SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009 3
(Date:7/29/2014)... With thirty days to go and almost 2500 ... Conference are well underway. The event, a joint venture ... and the French Society for Biochemistry and Molecular Biology ... Thursday, 4 September at the Palais des Congrs in ... largest meeting for the life sciences in Europe this ...
(Date:7/29/2014)... Achalasia is a rare disease it affects 1 in ... in the esophageal wall. While its cause remains unknown, a ... in Belgium, the University of Bonn in Germany and other ... autoimmune in origin. The study, published on 6 July in ... the mysterious disease. , When we swallow, a sphincter in ...
(Date:7/28/2014)... About 100 drugs already approved by the U.S. Food ... prevent the growth of certain bacterial pathogens inside human ... Mediterranean spotted fever. The findings, published in mBio ... for Microbiology, demonstrate a new way of identifying non-antibiotic ... , A handful of drugs on the list ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2
... Deepwater Horizon oil spill, a UC Santa Barbara scientist has ... oil will spread. He was able to forecast several days in ... parts of the Gulf of Mexico. "We predicted where the ... mechanical engineering at UC Santa Barbara who studies fluid dynamics. "We ...
... Singapore, September 3, 2010 Novartis announced today ... (NITD), in collaboration with researchers from the Genomics Institute ... and Public Health Institute and The Scripps Research Institute ... a next generation treatment for drug resistant malaria. Major ...
... N.Y. -- Twenty-first-century pharmaceutical breakthroughs require 21st-century drug ... molecular design and high-throughput screening of effective, new ... Buffalo symposium to be held Sept. 11 on ... Screening," which will feature a variety of cutting-edge ...
Cached Biology News:New method successfully predicted how oil from Deepwater Horizon spill would spread 2Novartis and collaborators discover novel antimalarial drug candidate 2Novartis and collaborators discover novel antimalarial drug candidate 3University at Buffalo symposium on in silico methods, high throughput screening 2University at Buffalo symposium on in silico methods, high throughput screening 3
... refrigerators, freezers, or liquid nitrogen. Conveniently sized to fit ... coding to project, user, lab, etc. Holes in the ... circulation. Supplied with 9 x 9 (12.7 mm cell) ... 13 x 13 x 5.1 cm H (5 1/4 ...
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
Biology Products: